| abstract |
The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, or pharmaceutical composition, comprising a pharmaceutical formulation based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The oral pharmaceutical composition comprises a pharmaceutical formulation and at least one modified-release agent. By Type IV-like, it is meant that the pharmaceutical formulation comprises no oil, for example no triglycerides or mixed glycerides. |